AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall

• AlloVir Inc (NASDAQ: ALVR) announced the final results from a Phase 2 study of posoleucel for BK viremia (BKV) in adult kidney transplant recipients.

• The data support the safety and antiviral activity of posoleucel.

• In Week 24 efficacy analysis, 39% (15/38) of patients who received posoleucel experienced a ≥1-log viral load reduction, more than double the placebo rate (14%; 2/14).

• Posoleucel dose response was observed, with a ≥1-log viral load reduction in the biweekly dosing group of 50% (10/20) vs. 28% (5/18) in the monthly dosing group, and 14% (2/14) in the placebo group.

• Repeat administration of posoleucel was generally well tolerated, with balanced safety across posoleucel dosing groups and placebo.

• In the high viral load stratum (≥10,000 copies/mL), 69% (11/16) of patients who received posoleucel overall and 75% (6/8) of patients in the biweekly dosing group achieved a ≥1-log viral load reduction vs. 25% (1/4) of patients in the placebo group.

• Allovir ended 2022 with a cash balance of $233.8 million. For 2023 the company expects operating expenses of $150-$170 million.

• Price Action: ALVR shares are down 2.58% at $6.41 on the last check Wednesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.